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A Ab bs st tr ra ac ct t
Breast cancer family history has been known to be one of the main cancer risk factors. Members of high-risk
families should be given recommendations which may improve prophylaxis, early diagnosis and treatment.
Detection of high-risk families is possible by identification of mutations in cancer susceptibility genes like BRCA1
and BRCA2 as well as by family history showing breast and/or ovary cancer aggregation. In a group of 521
breast cancer patients we identified 26 patients with hereditary breast cancer who fulfilled the following criteria:
one more relative with breast cancer, vertical transmission, at least one breast cancer patient affected at the
age under 50 years. 8 patients of these developed second primary breast cancer. We also compared the
frequency of hereditary cancers in stage I-III with the frequency of respective cancers with negative family history.
Hereditary breast cancers were diagnosed less frequently in stage I and more frequently in stage II and III
(RR=0.49, RR=1.39, RR=1.62, respectively). Because of importance of family history as well as genetic testing
for breast cancer susceptibility genes (BRCA1/2), it is necessary to create a nationwide network of hereditary
cancer clinics for proper diagnosis, treatment, and prophylaxis of these patients. 
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I In nt tr ro od du uc ct ti io on n   
Cancer family history has been known to be one of
the main risk factors. Members of high-risk families
should be given recommendations which may improve
prophylaxis, early diagnosis and treatment [1-4]. During
the last 10 years, the knowledge of cancer genetics has
increased substantially. Now it is possible to identify
several genes involved in the hereditary forms of some
types  of  cancers  including  breast  cancer  [5-6].
Hereditary forms of breast cancer are mostly caused by
mutations in such genes as BRCA1 and BRCA2 and are
thought to account for 5-10% of all cases of breast
cancer [3]. Because of high penetration of mutated
genes as well as autosomal dominant trait, female
family members are frequently affected with breast
cancer, therefore taking the family history is a major,
effective and cheap way of diagnosing hereditary forms
of breast cancer. Clinical outcome of hereditary breast
cancer differs from sporadic cases. Primary tumour
growth is different than sporadic ones, and it seems that
early detection of hereditary forms may be more difficult.
Affected patients with the hereditary form of breast
cancer are also at increased risk of the development of
the second primary breast cancer. The purpose of this
work was to evaluate in Lithuanian breast cancer
patients such clinical factors as: frequency of diagnosis
of primary breast cancer in clinical stage I-IV and
frequency of the second primary breast cancer in groups
with a hereditary form. In order to identify patients
suspected for hereditary breast cancer specific pedigree
criteria were applied. H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(2) 78
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M Ma at te er ri ia al ls s   a an nd d   m me et th ho od ds s
In 2001 in Vilnius University Institute of Oncology
there were 521 patients treated for breast cancer.
Patients suspected for site specific hereditary breast
cancer were identified according to the following
pedigree criteria: mother and daughter affected by
breast cancer; one of them developed breast cancer
under the age of 50 years. Every case of hereditary
breast cancer was analysed retrospectively by stage
according to TNM classification and compared with the
control group which was selected from sporadic cases
diagnosed in the same cancer centre and matched for
the same age of diagnosis. The frequency of each stage
rates was calculated for study and control groups. The
relative risk was used as an estimate of the relative
effectiveness for the recruitment cases by stage. Relative
risk was calculated by stage as a ratio at each category
to the total number of observation. The frequency of
the development of the second primary tumour in the
hereditary breast cancer group was calculated. 
R Re es su ul lt ts s   a an nd d   d di is sc cu us ss si io on n   
In a group of 521 patients treated with breast
cancer in Vilnius University Institute of Oncology in
2001, there were 26 patients from 25 families with
family history indicating diagnosis of site specific
hereditary breast cancer. All these patients were affected
with primary breast cancer under the age of 50 years,
which is in concordance with the early age of onset
observed in patients with positive breast cancer family
history. We evaluated the frequency of breast cancers
diagnosed in clinical stages I-IV in hereditary cancer
patients. To avoid possible differences in diagnostic
effectiveness between diagnostic centres in Lithuania,
a control group was selected from sporadic breast
cancer cases diagnosed in the same cancer centre and
matched for the same age of diagnosis. Comparison
of breast cancer frequencies diagnosed in clinical
stages I-IV is shown in Table 1. We observed much
lower frequency of hereditary cases diagnosed in stage
I than sporadic ones (11% vs. 23%, RR=0.49). In
contrast hereditary breast cancer cases were diagnosed
more often than sporadic tumours, in advanced stages
(stage II in 61% vs. 44%, RR=1.39; and stage III in
27% vs. 17%, RR=1.62, respectively). We have not
observed  any  hereditary  breast  cancer  patient
diagnosed in clinical stage IV, which can be caused by
the low number of studied cases. The low rate of
hereditary cancers diagnosed in stage I and high rate
of stage II and III may suggest that growth of these
tumours may be accelerated and standard surveillance
is less effective than in a group of patients without
family history. Similarly to other observations, cancer
family history is correlated with an increased risk of
contralateral breast cancer. In our group of 26 patients,
8 demonstrated bilateral breast cancer. Experience of
many foreign hereditary cancer centres proved that
hereditary cancer patients as well as their family
members must be followed in an institution prepared
for biological genetic testing and specialist surveillance.
A better understanding of the process of coupling in
healthy people with a genetic risk of cancer including
genetic consultations is relevant here to make a
decision about prevention or screening [7-11]. 
The results of this study show the need to create
a Lithuanian specialist centre for hereditary cancer
diagnosis, treatment, and prophylaxis, which will
coordinate  and  connect  work  between  different
specialists. 
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T Ta ab bl le e   1 1. .   Breast cancer in a study group and in a population by cancer stage
S St ta ag ge e   ( (T TN NM M) )    N Nu um mb be er r   o of f   c ca as se es s   i in n   a a s st tu ud dy y   g gr ro ou up p N Nu um mb be er r   o of f   c ca as se es s   i in n   a a p po op pu ul la at ti io on n* * R Re el la at ti iv ve e   r ri is sk k   ( (R RR R) )   
I 3 24 0.49 
II 16 45 1.39
III 7 17 1.62
IV 0 14 –
Unknown 0 2 –
Total 26 102 –
*) matched by age and territory with the study group, 2000H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(2) 79
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